Phase 1/2 safety, tolerability and efficacy study of binimetinib in combination with Opdivo (nivolumab), and Opdivo + Yervoy (ipilimumab) regimen

Trial Profile

Phase 1/2 safety, tolerability and efficacy study of binimetinib in combination with Opdivo (nivolumab), and Opdivo + Yervoy (ipilimumab) regimen

Planning
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Binimetinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Array BioPharma
  • Most Recent Events

    • 09 Aug 2017 According to an Array BioPharma media release, results from these and other study (CTP 284700) will be used to determine optimal approaches to further clinical development of the respective combinations.
    • 02 Jun 2017 New trial record
    • 30 May 2017 According to an Array BioPharma media release, results from this first study, which is anticipated to begin in the second half of 2017, will be used to determine optimal approaches to further clinical development of these combinations.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top